- Conditions
- Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA), Multiple Sclerosis, Dermatomyositis, Systemic Sclerosis (SSc)
- Interventions
- KYV-101
- Drug
- Lead sponsor
- Kyverna Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2041
- U.S. locations
- 1
- States / cities
- Denver, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Lupus Nephritis
- Interventions
- Ianalumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Orchard Park, New York
- Conditions
- Lupus Nephritis
- Interventions
- CNTO 136, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more
- Conditions
- Lupus Nephritis
- Interventions
- Iptacopan (part 1), Iptacopan (part 2), Placebo + standard of care, Iptacopan + placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Fontana, California • Irvine, California + 22 more
- Conditions
- Lupus Nephritis (LN)
- Interventions
- C-CAR168
- Biological
- Lead sponsor
- AbelZeta Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Lupus Nephritis (LN), Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus, SLE, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (Disorder)
- Interventions
- ONT01 is a small molecule CD11b modulator.
- Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lupus Erythematosus, Systemic, Lupus Nephritis
- Interventions
- CTLA4-IgG4m (RG2077), Cyclophosphamide
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 2
- States / cities
- San Francisco, California • New York, New York
- Conditions
- Lupus Nephritis
- Interventions
- Felzartamab
- Drug
- Lead sponsor
- HI-Bio, A Biogen Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- La Jolla, California • San Francisco, California • Stanford, California + 9 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Yuba City, California • Centennial, Colorado + 7 more
- Conditions
- Lupus Nephritis (LN)
- Interventions
- Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Lupus Nephritis
- Interventions
- Guselkumab Dose 1, Placebo, Guselkumab Dose 2, Standard-of-care treatment
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 8
- States / cities
- Covina, California • La Jolla, California • Los Angeles, California + 5 more
- Conditions
- Lupus Nephritis
- Interventions
- Voclosporin, Placebo Oral Capsule
- Drug
- Lead sponsor
- Aurinia Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Lupus Nephritis
- Interventions
- FT819, Fludarabine, Cyclophosphamide, Bendamustine
- Drug
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2042
- U.S. locations
- 16
- States / cities
- Beverly Hills, California • Fullerton, California • Irvine, California + 13 more
- Conditions
- Lupus Nephritis
- Interventions
- BI 655064 dose 1, BI 655064 dose 2, BI 655064 dose 3, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Doral, Florida • Kissimmee, Florida + 6 more
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis
- Interventions
- SYNCAR-001, STK-009
- Drug
- Lead sponsor
- Synthekine
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2041
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Hackensack, New Jersey • Manhasset, New York + 3 more
- Conditions
- Lupus Nephritis
- Interventions
- Laquinimod, Mycophenolate Mofetil, Prednisolone/Prednisone, Placebo, Methylprednisolone
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 10 more
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis, Idiopathic Inflammatory Myopathy
- Interventions
- KITE-363, Fludarabine, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Duarte, California • Stanford, California • Tampa, Florida + 1 more
- Conditions
- Lupus Nephritis
- Interventions
- BMS-986165, Placebo, Mycophenolate Mofetil
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Fresno, California • Los Angeles, California + 31 more
- Conditions
- Glomerulonephritis, Membranoproliferative, Lupus Nephritis
- Interventions
- BG9588
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lupus Nephritis, Lupus Erythematosus, Systemic
- Interventions
- Experimental - Test Results and Education
- Other
- Lead sponsor
- Qure Healthcare, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 166 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Lupus Nephritis
- Interventions
- BMS-188667, Mycophenolate mofetil, Prednisone, Placebo matching with BMS-188667
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 695 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Long Beach, California • San Leandro, California + 21 more
- Conditions
- Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis
- Interventions
- KYV-101, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- David Porter
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lupus Nephritis
- Interventions
- Rituximab, Cyclophosphamide, Prednisone, Methylprednisolone, Diphenhydramine, Acetaminophen, Belimumab
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Lupus Nephritis
- Interventions
- LUPKYNIS, belimumab, obinutuzumab or anifrolumab, mycophenolic acid analog (MPAA), corticosteroid
- Drug · Biological
- Lead sponsor
- Aurinia Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- La Mesa, California • Los Alamitos, California • Jacksonville, Florida + 11 more